Clinical Research Directory
Browse clinical research sites, groups, and studies.
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Sponsor: Johns Hopkins University
Summary
To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.
Official title: Isturisa in Management of Mild Autonomous Cortisol Secretion (MACS)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-02-02
Completion Date
2029-03
Last Updated
2026-03-05
Healthy Volunteers
No
Interventions
Osilodrostat (Isturisa)
The intervention aims to evaluate the impact of osilodrostat on cardiometabolic outcomes, bone mineral density, body composition, adrenal tumor size or hyperplasia, and biochemical markers of cortisol excess.
Locations (1)
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States